NasdaqCM - Nasdaq Real Time Price USD

RedHill Biopharma Ltd. (RDHL)

2.0000
+0.0300
+(1.52%)
At close: May 12 at 4:00:00 PM EDT
2.0000
0.00
(0.00%)
Pre-Market: 8:44:48 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
8,043
8,043
6,530
61,800
85,757
Cost of Revenue
3,192
3,192
3,459
33,337
49,406
Gross Profit
4,851
4,851
3,071
28,463
36,351
Operating Expense
17,105
17,105
34,503
71,307
117,486
Operating Income
-12,254
-12,254
-31,432
-42,844
-81,135
Net Non Operating Interest Income Expense
-1,852
-1,852
-2,158
-42,207
-16,581
Other Income Expense
5,838
5,838
57,506
13,382
-28
Pretax Income
-8,268
-8,268
23,916
-71,669
-97,744
Net Income Common Stockholders
-8,268
-8,268
23,916
-71,669
-97,744
Diluted NI Available to Com Stockholders
-8,268
-8,268
23,916
-71,669
-97,744
Basic EPS
0.00
--
100.00
-1.20k
-2.10k
Diluted EPS
0.00
--
100.00
-1.20k
-2.10k
Basic Average Shares
1,232.2720
--
259.1220
61.6300
46.5270
Diluted Average Shares
1,232.2720
--
259.1220
61.6300
46.5270
Total Operating Income as Reported
-14,613
-14,613
12,632
-42,844
-81,135
Total Expenses
20,297
20,297
37,962
104,644
166,892
Net Income from Continuing & Discontinued Operation
-8,268
-8,268
23,916
-71,669
-97,744
Normalized Income
-14,106
-14,106
-13,769.3400
-85,051
-97,716
Interest Income
133
133
94
140
51
Interest Expense
55
55
367
41,333
16,567
Net Interest Income
-1,852
-1,852
-2,158
-42,207
-16,581
EBIT
-8,213
-8,213
24,283
-30,336
-81,177
EBITDA
-7,594
-7,594
26,273
-22,182
-63,028
Reconciled Cost of Revenue
3,192
3,192
3,459
33,337
49,406
Reconciled Depreciation
619
619
1,990
8,154
18,149
Net Income from Continuing Operation Net Minority Interest
-8,268
-8,268
23,916
-71,669
-97,744
Total Unusual Items Excluding Goodwill
5,838
5,838
48,942
13,382
-28
Total Unusual Items
5,838
5,838
48,942
13,382
-28
Normalized EBITDA
-13,432
-13,432
-22,669
-35,564
-63,000
Tax Rate for Calcs
0
0
0.0002
0
0
Tax Effect of Unusual Items
0
0
11,256.6600
0
0
12/31/2021 - 1/7/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CPIX Cumberland Pharmaceuticals Inc.
5.27
+12.13%
 
EVOK Evoke Pharma, Inc.
3.1550
-1.41%
 
SBFM Sunshine Biopharma, Inc.
1.3500
+8.00%
 
AKAN Akanda Corp.
1.1998
+1.68%
 
SBFMW Sunshine Biopharma, Inc.
0.1985
+16.76%
 
LVVV LiveWire Ergogenics, Inc.
0.0007
+16.67%
 
KMDA Kamada Ltd.
6.82
-0.87%
 
ESAIY Eisai Co., Ltd.
6.76
-2.45%
 
DERM Journey Medical Corporation
6.83
-0.73%
 
GELS Gelteq Limited
1.4400
+5.11%